Pulse Biosciences (PLSE) has placed its nPulse Cardiac Catheter Ablation System at the center of its plans, following European feasibility data in Atrial Fibrillation and upcoming pivotal studies and conference presentations.

These AFib data and the new focus on the nPulse Cardiac Catheter program come after a strong run, with a 90 day share price return of 45.39% and a very large 3 year total shareholder return. At the same time, the 1 year total shareholder return of 37.61% and 5 year total shareholder return of 4.29% together suggest that momentum has recently been building from a relatively flat longer term base.

If this kind of medical technology story interests you, it can be useful to see what else is gaining attention in the sector and beyond through the 36 healthcare AI stocks.

With shares up sharply over the past year and the price still sitting below a US$30 analyst target, the key question now is whether Pulse Biosciences is still undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 50% Overvalued

Pulse Biosciences last closed at $22.10, compared with a most followed narrative fair value estimate of $22.00, which points to a modest premium and a lot of expectation already in the price.

Advancing clinical programs for the nPulse cardiac surgical clamp and nPulse 360 Catheter in atrial fibrillation, including FDA IDE approval, breakthrough designation, and expanding EU feasibility data, creates a path to entry in a high value EP and cardiac surgery market that can expand the company’s addressable revenue base and long term earnings power.

Curious what kind of revenue ramp and margin shift that vision assumes? This narrative leans on sharp top line growth and a rich future earnings multiple. The numbers behind that view are anything but conservative.

Result: Fair Value of $22 (OVERVALUED)

However, this situation could change quickly if clinical trials do not clearly outperform existing treatments, or if higher expenses and limited revenue keep cash burn elevated.

Next Steps

If this mix of optimism and concern around Pulse Biosciences leaves you undecided, it may be helpful to act promptly and evaluate the data yourself using the 1 key reward and 3 important warning signs.

Looking for more investment ideas?

Do not stop with a single stock when there are clear, data driven ways to spot other opportunities using the Simply Wall St Screener that many investors overlook.

• Target potential mispricings by reviewing companies that screen as 53 high quality undervalued stocks before attention fully shifts their way.
• Secure more predictable income streams by checking out the 13 dividend fortresses that could suit a yield focused watchlist.
• Prioritise resilience by focusing on 68 resilient stocks with low risk scores that may help balance out bolder positions in your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.